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Results Luciferase assays showed that miR-608 targeted 
RRM1 and CDA genes in 293T, AsPC-1 and MIA PaCa-2 
cell lines. Compared to parental cell line, resistant MIA 
PaCa-2 and AsPC-1 cells demonstrated increased expres-
sion of RRM1 and CDA. On the other hand the expression 
of miR-608 in resistant MIA PaCa-2 and AsPC-1 cells was 
lower than parental cells. Furthermore, transfection of MIA 
PaCa-2 and AsPC-1 cells by miR-608 lead to decreased 
expression of RRM1 and CDA and lowered viability of the 
cells in comparison with scrambled microRNA transfected 
cells.
Conclusion During resistance induction in pancreatic can-
cer cells, miR-608 which is targeting RRM1 and CDA is 
downregulated which leads to upregulation of these genes.
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Abbreviations
PDAC  Pancreatic adenocarcinoma
GEM  Gemcitabine
CDA  Cytidine deaminase
RRM1  Ribonucleotide reductase M1
dNTP  Deoxynucleoside triphosphate
miR  miRNA, microRNA
dFdU  2′2′-Difluorodeoxyuridine
IC  Inhibitory concentration
MTT  3-(4,5-Di methylthiazole-2-yl)-2, 5-biphenyl 
tetrazolium bromide
Abstract 
Purpose Gemcitabine resistance is the main problem in 
pancreatic adenocarcinoma patients. Hence, we aimed to 
identify the correlation between expression of RRM1 and 
CDA as the resistance genes and their predicted target-
ing miR-608 in the resistant pancreatic cancer cell lines to 
gemcitabine.
Methods Dual luciferase assay was performed to determine 
whether both RRM1 and CDA are targeted by miR-608 in 
293T and pancreatic cancer cell lines. AsPC-1 and MIA 
PaCa-2 cell lines became gradually resistant to gemcitabine 
by exposing to the increasing doses of gemcitabine. After 
RNA and miRNAs extraction and cDNA conversion, the 
expressions of RRM1, CDA and miR-608 in all cell lines 
were studied by quantitative PCR. Pre-miR-608 transfection 
to the cell lines was done by calcium phosphate method. 
MTT assay was performed for analyzing the chemo sensitiv-
ity of different cell lines to gemcitabine.
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